新型冠状病毒受体血管紧张素转换酶2的研究进展  

Research Progress on Angiotensin Converting Enzyme 2 as the Receptor of SARS-CoV-2

作　　者：郭建淑[1] 张燕[2] 孙学春[1] 钟萍[1] GUO Jianshu;ZHANG Yan;SUN Xuechun;ZHONG Ping(Geriatric Department of Cardiology,Sichuan Academy of Medical Sciences&Siehuan Provieial People's Hospital,Chengdu 610072,China;Respiratory medicine department,Sichuan Academy of Medical Sciences&Siehuan Provieial People's Hospital,Chengdu 610072,China)

机构地区：[1]四川省医学科学院·四川省人民医院老年心血管科,成都610072 [2]四川省医学科学院·四川省人民医院呼吸科,成都610072

出　　处：《病毒学报》2020年第6期1165-1170,共6页Chinese Journal of Virology

摘　　要：自新型冠状病毒肺炎暴发以来,中国已累计超过8万例患者。随着对其病毒结构和感染机制的深入研究,研究者们发现血管紧张素转换酶(Angiotensin converting enzyme,ACE)2是新型冠状病毒(SARS-CoV-2)的受体。根据既往的研究,ACE2是肾素血管紧张素系统(Renin angiotensin system,RAS)的关键酶之一,与其同源物ACE在该系统中起协同调节作用,同时,其生理调节功能也广泛作用于心血管、肾脏、肝脏、肠道等。疫情暴发后,人们急于了解SARS-CoV-2的溯源、中间宿主、流行病学分析和治疗的靶点,ACE2身份的转变使其成为研究的热点之一。本文就目前ACE2在SARS-CoV-2和心血管等领域的研究进展进行简要综述,以期为SARS-CoV-2的溯源、跨物种传播、流行病学分析以及抗病毒药物靶点研究提供参考依据。There have been nearly 80,000 cases in the world since the outbreak of novel coronavirus pneumonia.With the study on viral structure and infection mechanism,researchers have found that angiotensin converting enzyme 2(ACE2)is the receptor of SARS-CoV-2.According to previous studies,ACE2 is one of the key enzymes in the RAS system.It plays a regulatory role with its homologue,namely ACE.The physiological function can be found in angiocarpy,kidney,liver,intestine and so on.The outbreak of novel coronavirus pneumonia makes people eager to know the viral source,intermediate host,epidemiological analysis and therapeutic targets.Then ACE2 becomes a research hotspot.In this review,we discuss the research advance of ACE2 in SARS-CoV-2 and cardiovascular diseases to provide references for tracing,cross-species transmission,epidemiological analysis and antiviral treatment of SARS-CoV-2.

关 键 词：新型冠状病毒肺炎 COVID-19 新型冠状病毒(SARS-CoV-2) 受体 血管紧张素转换酶2(ACE2) 

分 类 号：R373.1[医药卫生—病原生物学] R511[医药卫生—基础医学]